Patents by Inventor Gregory Paul Winter
Gregory Paul Winter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6806079Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: GrantFiled: November 28, 2000Date of Patent: October 19, 2004Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Publication number: 20040192897Abstract: An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequence for producing the altered antibody may be produced by site-directed mutagenesis using long oligonucleotides or using gene synthesis.Type: ApplicationFiled: January 24, 2003Publication date: September 30, 2004Applicant: Medical Research CouncilInventor: Gregory Paul Winter
-
Publication number: 20040157215Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: ApplicationFiled: March 18, 2004Publication date: August 12, 2004Applicants: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Publication number: 20040157214Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: ApplicationFiled: March 18, 2004Publication date: August 12, 2004Applicants: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Henricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kaspar Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Publication number: 20040127688Abstract: An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequence for producing the altered antibody may be produced by site-directed mutagenesis using long oligonucleotides or using gene synthesis.Type: ApplicationFiled: January 24, 2003Publication date: July 1, 2004Applicants: Medical Research Council, BTG International LimitedInventor: Gregory Paul Winter
-
Publication number: 20040110941Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the productions of Ig-type molecules and said ligands or receptors, and the use of said ligand or receptors in therapy, diagnosis or catalysis.Type: ApplicationFiled: November 8, 2002Publication date: June 10, 2004Applicant: Medical Research CouncilInventors: Gregory Paul WINTER, Elizabeth Sally WARD, Detlef GUSSOW
-
Publication number: 20040058400Abstract: Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.Type: ApplicationFiled: September 20, 2002Publication date: March 25, 2004Applicant: Medical Research CouncilInventors: Kaspar-Philipp Holliger, Andrew David Griffiths, Hendricus Renerus Jacobus Matheus Hoogenboom, Magnus Malmqvist, James David Marks, Brian Timothy McGuinness, Anthony Richard Pope, Terence Derek Prospero, Gregory Paul Winter
-
Publication number: 20040009507Abstract: An in vitro method for constructing a concatenated head-to-tail repertoire of target nucleic acid sequences is revealed. In particular, the method relates to cycles of concatenation whereby after a single cycle of concatenation, not more than two identical copies of each target nucleic acid sequence are linked together head-to-tail on the same molecule of DNA. The present method ensures that each molecule of a concatenated repertoire is derived from a single template target sequence of the starting repertoire.Type: ApplicationFiled: April 11, 2003Publication date: January 15, 2004Applicant: Domantis, Ltd.Inventors: Gregory Paul Winter, Laurent Jespers, Ignace Lasters, Peter Wang
-
Publication number: 20030190674Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: ApplicationFiled: December 19, 2002Publication date: October 9, 2003Applicant: Medical Research CouncilInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6593081Abstract: Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.Type: GrantFiled: March 21, 2000Date of Patent: July 15, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Publication number: 20030130496Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.Type: ApplicationFiled: November 8, 2002Publication date: July 10, 2003Applicant: Medical Research CouncilInventors: Gregory Paul Winter, Elizabeth Sally Ward, Detlef Gussow
-
Patent number: 6589527Abstract: Antibodies are retargeted to a target for which they have no functional specificity under normal circumstances. Use is made of a multi-specific binding substance which has binding specificity for the target and anti-antibody binding specificity. The binding substance may comprise an immunoglobulin antigen binding site and may be a “diabody”. Depending on the antibody bound, effector functions such as Complement, ADCC and immune blocking are recruited to act on the target. Example targets are human cells. In vivo and in vitro utilities are exemplified, including lysis of tumor cells and agglutination of red blood cells.Type: GrantFiled: March 22, 1996Date of Patent: July 8, 2003Assignee: Medical Reseach CouncilInventors: Gregory Paul Winter, Kaspar Philipp Holliger
-
Patent number: 6582915Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 28, 2000Date of Patent: June 24, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Publication number: 20030114659Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.Type: ApplicationFiled: November 8, 2002Publication date: June 19, 2003Applicant: Medical Research CouncilInventors: Gregory Paul Winter, Elizabeth Sally Ward, Detlef Gussow
-
Patent number: 6555313Abstract: Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.Type: GrantFiled: May 16, 2000Date of Patent: April 29, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Publication number: 20030078192Abstract: The invention relates to a pharmaceutical composition comprising a chimeric, folded protein domain comprising two or more sequence segments from parent amino acid sequences that are not homologous. The invention more particularly relates to compositions comprising a chimeric, folded protein domain comprising two or more sequence segments wherein each of the sequence segments: is not designed or selected to consist solely of a single complete protein structural element and is not designed or selected to consist solely of an entire protein domain; and, in isolation, shows no significant folding at the melting temperature of the chimeric protein. The invention also relates to methods for the selection of such protein domains, and to methods of raising an immune response using such domains, and preferably to chimeric domains that display conformational B cell epitopes of at least one of their parent amino acid sequences.Type: ApplicationFiled: April 10, 2002Publication date: April 24, 2003Inventors: Gregory Paul Winter, Lutz Riechmann
-
Patent number: 6548640Abstract: The invention relates to altered antibodies that have a heavy or light chain variable domain in which the framework regions differ from the framework regions naturally associated with the complementarity determining regions of the variable domain and in which the framework regions are derived from a source of framework regions that differs from the framework regions naturally associated with the complementarity determining regions of the variable regions.Type: GrantFiled: May 26, 1995Date of Patent: April 15, 2003Assignee: BTG International LimitedInventor: Gregory Paul Winter
-
Patent number: 6545142Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.Type: GrantFiled: November 28, 2000Date of Patent: April 8, 2003Assignee: Medical Research Council of the United KingdomInventors: Gregory Paul Winter, Elizabeth Sally Ward, Detlef Güssow
-
Patent number: 6544731Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 20, 1998Date of Patent: April 8, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6521404Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 20, 1998Date of Patent: February 18, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg